15 Safe Stocks to Invest In For Beginners

Page 2 of 10

14. Pfizer Inc. (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) is expanding into the cancer treatment market. The $43 billion acquisition of Seagen has begun to pay off, with Pfizer now controlling a dominant share of the Antibody-Drug Conjugate (ADC) market, a category most high profile investors view as the next frontier of high-margin biotech. The firm plans to initiate 20 pivotal studies in 2026, including 10 for the obesity candidates acquired from Metsera and 4 for high-priority oncology assets. For 2026, Pfizer has guided for roughly $5 billion in COVID-related revenue. When excluding COVID products, the core portfolio of the firm grew 6% operationally in late 2025.

The cost realignment and operational discipline of Pfizer Inc. (NYSE:PFE) must also be mentioned, two key metrics favored by defensive investors. The firm successfully executed a $4 billion cost-cutting program in 2025 and the smart money is betting that the current management, under increased scrutiny, will prioritize R&D efficiency over the scattered M&A of previous years. From a quantitative perspective, Pfizer is currently one of the cheapest mega-cap pharmaceutical stocks. The stock is trading at roughly 9.3x forward earnings, compared to an industry average of over 18x. With a dividend yield holding steady at around 6.2%, investors are using the stock as an income generator.

Page 2 of 10